NSCLC Stage III Clinical Trials

11 recruitingLast updated: June 18, 2026

There are 11 actively recruiting nsclc stage iii clinical trials across 7 countries. Studies span Phase 2, Not Applicable, Phase 3. Top locations include Angers, France, Berlin, Germany, Bordeaux, France. Updated daily from ClinicalTrials.gov.


NSCLC Stage III Trials at a Glance

11 actively recruiting trials for nsclc stage iii are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Angers, Berlin, and Bordeaux. Lead sponsors running nsclc stage iii studies include Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Goethe University, and Arbeitsgemeinschaft medikamentoese Tumortherapie.

Browse nsclc stage iii trials by phase

Treatments under study

About NSCLC Stage III Clinical Trials

Looking for clinical trials for NSCLC Stage III? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new NSCLC Stage III trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about NSCLC Stage III clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

NSCLC Stage IVNSCLC Stage III
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer30 enrolled20 locationsNCT06552234
Recruiting
Phase 3

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Non-small Cell Lung CancerNSCLCNSCLC Stage III
Maximilian Diehn48 enrolled1 locationNCT04585490
Recruiting
Phase 2

Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

NSCLC Stage IINSCLC Stage III
Shanghai Pulmonary Hospital, Shanghai, China54 enrolled1 locationNCT07410975
Recruiting
Not Applicable

PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study

NSCLC Stage IINSCLC Stage III
University of Utah20 enrolled2 locationsNCT06945484
Recruiting
Not Applicable

A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

NSCLC Stage IVNSCLC Stage III
Jinzhou Medical University80 enrolled1 locationNCT06512207
Recruiting

Lung Cancer Registry

Lung CancerNSCLC Stage IVNSCLC Stage III+2 more
Arbeitsgemeinschaft medikamentoese Tumortherapie500 enrolled3 locationsNCT04654364
Recruiting
Phase 2

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

NSCLC Stage IVNSCLC Stage IIIB
Goethe University50 enrolled16 locationsNCT05281406
Recruiting

A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced

Non-small Cell Lung CancerNSCLCNSCLC, Stage I+1 more
MSD Italia S.r.l.600 enrolled25 locationsNCT06467383
Recruiting
Phase 2

Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC

NSCLC Stage IINSCLC, Stage IIIANSCLC Stage IIIB
University Hospital Heidelberg20 enrolled1 locationNCT04865250
Recruiting

Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients

NSCLC Stage IIILocally Advanced Lung Carcinoma
Jun Zhang, MD, PhD44 enrolled2 locationsNCT04680377
Recruiting
Phase 2

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer

OncologyNSCLC Stage IVNSCLC Stage III
Vestre Viken Hospital Trust138 enrolled1 locationNCT05344209